Skip to content
10-Q

Quarterly Report

Fusion Pharmaceuticals Inc.

0000950170-24-053958

← back to feed
Filed
May 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 29, 2024 85.06M sh
Shares Diluted Q1 2024 · Mar 31, 2024 83.78M sh
Shares Diluted Q1 2024 · Mar 31, 2023 53.78M sh
Capex Q1 2024 · Mar 31, 2024 $1.33M
Capex Q1 2024 · Mar 31, 2023 $1.22M
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$27.31M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$25.44M
Long Term Debt Q1 2024 · Mar 31, 2024 $49.69M
Long Term Debt Q1 2024 · Dec 31, 2023 $34.78M
Long Term Debt restated Q1 2024 · Mar 31, 2023 $34.78M
Short Term Debt Q1 2024 · Mar 31, 2024 $50M
Short Term Debt Q1 2024 · Mar 31, 2023 $35M
Short Term Investments Q1 2024 · Mar 31, 2024 $182.74M
Short Term Investments Q1 2024 · Dec 31, 2023 $172.15M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $27.79M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $61.46M
Stockholders Equity Q1 2024 · Mar 31, 2024 $241.83M
Stockholders Equity Q1 2024 · Dec 31, 2023 $222.48M
Stockholders Equity Q1 2024 · Mar 31, 2023 $200.83M
Stockholders Equity Q1 2024 · Dec 31, 2022 $162.22M
Current Liabilities Q1 2024 · Mar 31, 2024 $20.76M
Current Liabilities Q1 2024 · Dec 31, 2023 $16.22M
Total Liabilities Q1 2024 · Mar 31, 2024 $81.98M
Total Liabilities Q1 2024 · Dec 31, 2023 $63.36M
Current Assets Q1 2024 · Mar 31, 2024 $220.92M
Current Assets Q1 2024 · Dec 31, 2023 $243.4M
Total Assets Q1 2024 · Mar 31, 2024 $323.81M
Total Assets Q1 2024 · Dec 31, 2023 $285.84M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.40
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.45
Eps Basic Q1 2024 · Mar 31, 2024 −$0.40
Eps Basic Q1 2024 · Mar 31, 2023 −$0.45
Sga Expense Q1 2024 · Mar 31, 2024 $14.55M
Sga Expense Q1 2024 · Mar 31, 2023 $9.01M
Rd Expense Q1 2024 · Mar 31, 2024 $21.31M
Rd Expense Q1 2024 · Mar 31, 2023 $15.88M
Net Income Q1 2024 · Mar 31, 2024 −$33.67M
Net Income Q1 2024 · Mar 31, 2023 −$24.29M
Operating Income Q1 2024 · Mar 31, 2024 −$35.86M
Operating Income Q1 2024 · Mar 31, 2023 −$24.86M
Revenue Q1 2024 · Mar 31, 2023 $28K